Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
29 April 2020 |
Main ID: |
EUCTR2008-003610-94-DE |
Date of registration:
|
31/10/2008 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Long-term study to collect additional information to evaluate the safety
and tolerability of BAY 63-2521 in different doses
|
Scientific title:
|
Long-term extension, multi-centre, multi-national study to evaluate the safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptomatic Pulmonary Arterial Hypertension (PAH). - PATENT-2 study |
Date of first enrolment:
|
26/11/2008 |
Target sample size:
|
462 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-003610-94 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): no
Therapeutic confirmatory - (Phase III): yes
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Argentina
|
Australia
|
Austria
|
Belgium
|
Brazil
|
Canada
|
China
|
Czech Republic
|
Denmark
|
France
|
Germany
|
Greece
|
Ireland
|
Israel
|
Italy
|
Japan
|
Korea, Republic of
|
Mexico
|
Netherlands
|
New Zealand
|
Poland
|
Portugal
|
Russian Federation
|
Singapore
|
Spain
|
Sweden
|
Switzerland
|
Taiwan
|
Thailand
|
Turkey
|
United Kingdom
|
United States
|
Contacts
|
Name:
|
Bayer Clinical Trials Contact
|
Address:
|
CTP-Team / Ref:"EU CTR" Bayer Pharma AG
13342
Berlin
Germany |
Telephone:
|
|
Email:
|
clinical-trials-contact@bayerhealthcare.com |
Affiliation:
|
Bayer HealthCare AG |
|
Name:
|
Bayer Clinical Trials Contact
|
Address:
|
CTP-Team / Ref:"EU CTR" Bayer Pharma AG
13342
Berlin
Germany |
Telephone:
|
|
Email:
|
clinical-trials-contact@bayerhealthcare.com |
Affiliation:
|
Bayer HealthCare AG |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: • Patients who have completed 12 weeks of treatment in the double blind trial
PATENT-1.
• Patients must have given their written informed consent to participate in the
study after having received adequate previous information and prior to any
study-specific procedures. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria: •Patient’s participating in another clinical trial
•Patients who have an ongoing serious adverse event from PATENT-1 that is
assessed as related to BAY 63-2521 are not allowed to participate in the
extension trial.
• Pregnant women(i.e. positive serum ß-human-chorionic-gonadotropin test or other signs of pregnancy) or breast feeding women, or or women with childbearing potential not using a combination of safe contraception methods
• Patients with a medical disorder, condition, or history of such that would impair
the patient's ability to participate or complete this study in the opinion of the
investigator or the sponsor.
• Pertinent non compliance with the conditions for the trial or instructions by the investigator during PATENT-1 participation.
• Patients with hypersensitivity to the investigational drug or inactive
constituents.
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Pulmonary Arterial Hypertension (PAH) MedDRA version: 15.1
Level: PT
Classification code 10064911
Term: Pulmonary arterial hypertension
System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders
|
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
|
Intervention(s)
|
Product Name: BAY 63-2521 tablets 0.5 mg Product Code: BAY 63-2521 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: riociguat CAS Number: 625115-55-1 Current Sponsor code: BAY 63-2521 Other descriptive name: Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 0.5-
Product Name: BAY 63-2521 tablets 1 mg Product Code: BAY 63-2521 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: riociguat CAS Number: 625115-55-1 Current Sponsor code: BAY 63-2521 Other descriptive name: Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1-
Product Name: BAY 63-2521 tablets 1.5 mg Product Code: BAY 63-2521 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: riociguat CAS Number: 625115-55-1 Current Sponsor code: BAY 63-2521 Other descriptive name: Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 1.5-
Product Name: BAY 63-2521 tablets 2 mg Product Code: BAY 63-2521 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: riociguat CAS Number: 625115-55-1 Current Sponsor code: BAY 63-2521 Other descriptive name: Methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo [3,4-b]pyridine-3-yl]-5-pyrimidinyl(methyl)carb Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 2-
Product Name: BAY 63-2521 tablets 2.5 mg Product Code: BAY 63-2521 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: riociguat CAS Number: 625115-55-1 C
|
Primary Outcome(s)
|
Primary end point(s): Safety (adverse events collection) and tolerability will be assessed in the long term treatment (until end of trial)
|
Secondary Objective:
|
Timepoint(s) of evaluation of this end point: Until end of the trial
|
Main Objective: to evaluate the long-term safety and tolerability of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in in treatment naive patients and patients pretreated with an Endothelin Receptor Antagonist or a Prostacyclinanalogue with symptomatic Pulmonary Arterial Hypertension (PAH)
|
Secondary Outcome(s)
|
Secondary end point(s): To provide an indication of maintenance of efficcacy with long term tretatment the following assessment are included:
- change from baseline in 6 Minute walking distance
- change from baseline in NT-proBNP
- change from baseline in WHO functional class
- Time to Clincal Worsening
- change from baseline in Borg CR10 Scale
- change from baseline in EQ-5D questionnarie
- change from baseline in LPH questionnarie
Additional HEOR endpoints:
- change in use of healthcare resources
|
Timepoint(s) of evaluation of this end point: Until end of the trial
|
Secondary ID(s)
|
BAY63-2521/12935
|
Source(s) of Monetary Support
|
Bayer HealthCare AG
|
Ethics review
|
Status: Approved
Approval date: 26/11/2008
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|